StocksRunner logo
mail
search
 
menu
 
ALX Oncology Holding
0.46
-4.94%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

ALXO

 

ALX Oncology Holding

$0.46

 
-$0.02 | -4.94%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
52W High
$ 17.50
 
 
MKT CAP
$ 24.78M
 
52W Low
$ 0.44
 
 
VOL
$ 839.08K
 
P/E Ratio
N/A
 
 
AVG VOL
$ 499.25K
 
RSI
 
 
TREND
Sideways
 
 
 

Chart

 
 

0.66

1.08

1.62

13.17

 
 
1year
6month
3month
1month
 
ALXO Latest Headlines +
 
 
 
StocksRunner

Explore our ALXO Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored ALXO Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our ALXO Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner
Overview
 
StocksRunner
Trending
 
StocksRunner
Screener
 
StocksRunner
Ideas
 
StocksRunner
Top Rated
 
StocksRunner
Momentum
 
StocksRunner
Earnings
 
 

Most Trending

 
 
 
Top Banner
 
  Overview  
  
  Analysis  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

ALXO

 

ALX Oncology Holding

$0.46

 
-$0.02 | -4.94%
 

 

Chart

 
 

0.66

1.08

1.62

13.17

 
 
1year
6month
3month
1month
 
 
 
 

ALXO Latest Headlines

 
 
 

ALX Oncology GAAP EPS of -$0.58 misses by $0.10.

 

Today

 
Earnings

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update. Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&.D Day in March Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC studies in mid-2025IND clearance received from United States FDA for novel EGFR-targeted antibody-drug conjugate (ADC) ALX2004 paving way for mid-year clinical program initiation. Company to host

 

Today

 
Activity

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma.

 

Fri Apr 25, 2025

 
Activity

 
 
 
 
 
StocksRunner

Discover ALXO Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of ALXO. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our ALXO Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ALXO Stock trends

ALXO Stock performance

ALXO Stock analysis

ALXO investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 
Post ×
 
0/666
joker